Works matching IS 0195668X AND DT 2018 AND VI 39 AND IP 27
Results: 21
New prospects for PCSK9 inhibition?
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2600, doi. 10.1093/eurheartj/ehy147
- By:
- Publication type:
- Article
Pathological phenotypes of LDL particles.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2574, doi. 10.1093/eurheartj/ehy387
- By:
- Publication type:
- Article
PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2586, doi. 10.1093/eurheartj/ehy311
- By:
- Publication type:
- Article
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2540, doi. 10.1093/eurheartj/ehx450
- By:
- Publication type:
- Article
Russian National Congress of Cardiology 2018.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2525, doi. 10.1093/eurheartj/ehy325
- Publication type:
- Article
Superior and inferior vena cava obstruction: an unusual presentation of a rare primary cardiac tumour.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2604, doi. 10.1093/eurheartj/ehy349
- By:
- Publication type:
- Article
Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2562, doi. 10.1093/eurheartj/ehy319
- By:
- Publication type:
- Article
‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2546, doi. 10.1093/eurheartj/ehx710
- By:
- Publication type:
- Article
‘The lower the better’ revisited: low-density lipoprotein and lipoprotein(a).
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2509, doi. 10.1093/eurheartj/ehy444
- By:
- Publication type:
- Article
Variability in atherogenic lipoproteins and coronary artery disease progression.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2559, doi. 10.1093/eurheartj/ehy348
- By:
- Publication type:
- Article
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2526, doi. 10.1093/eurheartj/ehy182
- By:
- Publication type:
- Article
Are the proprotein convertase subtilisin/kexin type 9 inhibitors new therapeutic chance for patients with familial hypercholesterolaemia and liver failure?
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2602, doi. 10.1093/eurheartj/ehy361
- By:
- Publication type:
- Article
Cardiac manifestation of polyarteritis nodosa.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2603, doi. 10.1093/eurheartj/ehy090
- By:
- Publication type:
- Article
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2589, doi. 10.1093/eurheartj/ehy334
- By:
- Publication type:
- Article
CIT 2018: A New Era, New JourneyReport from the China Interventional Therapeutics (CIT) 2018, the largest interventional cardiology scientific congress in the Asia-Pacific region.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2515, doi. 10.1093/eurheartj/ehy322
- By:
- Publication type:
- Article
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2577, doi. 10.1093/eurheartj/ehy122
- By:
- Publication type:
- Article
Hugo A. Katus MD PhD FESCAfter discovering troponin as a biomarker Katus reached out to genome research, improving healthcare in hospitals, and actively teaching, to fill a 13-hour workday schedule.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2513, doi. 10.1093/eurheartj/ehy321
- By:
- Publication type:
- Article
The ESC Publications Ethics CommitteeReport from the first 5 years’ experience of the European Society of Cardiology (ESC) journals family ethics committee.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2518, doi. 10.1093/eurheartj/ehy323
- By:
- Publication type:
- Article
Hands-on training in acute cardiac careReport from the first-ever Acute Cardiovascular Care School in Madrid, Spain, November 2017.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2521, doi. 10.1093/eurheartj/ehy324
- By:
- Publication type:
- Article
Lipoprotein(a): the perpetual supporting actor.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2597, doi. 10.1093/eurheartj/ehy385
- By:
- Publication type:
- Article
Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2551, doi. 10.1093/eurheartj/ehy209
- By:
- Publication type:
- Article